Some aspects of pharmacological support with antidysrhythmic drugs

Cover Page

Abstract

A high level of morbidity and mortality from cardiovascular diseases remains prevalent in the Russian Federation, despite a decreasing trend that emerged in recent years. Rhythm and conduction disorders play an essential role in the thanatogenesis of cardiovascular pathology, which determines the medical and social significance of their pharmacotherapy. This is indicated by the stable demand for antidysrhythmic drugs from both the state and the population. This is evidenced by high levels of public procurements and retail sales of “drugs for the treatment of cardiovascular diseases,” since patients take this drug group for a long time and often permanently. Our marketing analysis of the antidysrhythmic drugs market used current open data from the State Register of Medicines and the State Register of Maximum Selling Prices and available analytical data. It showed that from 54.5% (metoprolol drugs) to 100% (procainamide drugs) of the market share is occupied by generic drugs made in Russia. The presented analysis confirms the assumption of a significant increase in the share of generic drugs in public procurements. This is associated with the implementation of the drug safety program for vital and essential drugs and the optimization of costs by the state. A priority of the state drug policy in Russia is to monitor the effectiveness and safety throughout its entire life cycle. Moreover, particular importance should be given to the issue of interchangeability, which is regulated by Federal Law No. 1360 dated September 5, 2020, “On the Procedure for Determining the Interchangeability of Medicines for Medical Use.” The annual increase in the share of generic domestic antidysrhythmic drugs on the market poses the problem of selecting the most efficient and safe approach to pharmacotherapy for practicing specialists. The solution may be to develop and implement open automated information systems for the safety profiles of the original and generic antidysrhythmic drugs.

Full Text

Restricted Access

About the authors

Vladimir V. Archipov

Scientific Centre for Expert Evaluation of Medicinal Product

Email: arkhipov2005@rambler.ru
ORCID iD: 0000-0002-1441-3418

 MD, Dr. Sci. (Med.)

Russian Federation, 8/2 Petrovsky Boulevard, 127051, Moscow

Yuliya R. Bolsunovskaya

Scientific Centre for Expert Evaluation of Medicinal Product

Author for correspondence.
Email: bolsunovskaya@expmed.ru
ORCID iD: 0000-0002-8721-0005
Russian Federation, 8/2 Petrovsky Boulevard, 127051, Moscow

References

  1. Ageeva LI. Healthcare in Russia. Moscow: Rosstat; 2019. (In Russ).
  2. Ulumbekova GE. Healthcare of Russia: results of activities 2012–2016. Urgent Measures in 2017–2018. ORGZDRAV: news, opinions, training. Bulletin of the Higher School of Economics. 2017;(1):8–12. (In Russ).
  3. Ulumbekova GE. Healthcare of Russia: 2018–2024 What to do? ORGZDRAV: news, opinions, training. Bulletin of the Higher School of Education. 2018(11):9–17. (In Russ).
  4. Mazur NA. Sudden death of patients with ischemic heart disease. Moscow: Medicine; 1985. (In Russ).
  5. Goldstein S, Bayes-de-Luna A, Gumdo-Soldevila J. Sudden cardiac death. Armonk: Futura; 1994.
  6. Medgate.ru/article/ [Internet]. Treatment of cardiac arrhythmias. [access date: 07.12.2020]. Avalible from: http://www.medgate.ru/article/16/117858 (In Russ).
  7. Dsm.ru/docs/analytics/ [Internet]. Russian pharmaceutical market: results of 2018. [cited 2020 Dec 07]. Available from: https://dsm.ru/docs/analytics/Annual_report_2018_DSM.pdf (In Russ).
  8. Dsm.ru/marketing/free-information/analytic-reports/ [Internet] Russian pharmaceutical market. Monthly analytical reviews of the market for the period for 2017 and for 2018, monthly. [cited 2020 Jul 12]. Available from: https://dsm.ru/marketing/free-information/analytic-reports/ (In Russ).
  9. Ulumbekova GE, Kalashnikova AV. Analysis of the pharmaceutical market in the Russian Federation ORGZDRAV: news, opinions, training. Bulletin of the Higher School of Education. 2018;(4):53–76. (In Russ).
  10. Dsm.ru/news/695/ [Internet] Overview of the pharmaceutical segment of pharmaceuticals for 2019. [cited 2020 Dec 07]. Available from: https://dsm.ru/news/695/ (In Russ).
  11. Batishcheva GA, Mubarakshina OA, Kurbatova EI. Original and reproduced drugs in cardiology: problems of interchangeability of bisoprolol drugs. Consilium Medicum. 2016;18(10):50–54. (In Russ).
  12. Vyshemirskaya EV, Ganicheva LM. Analysis of consumer preferences when choosing antiarrhythmic drugs. Bulletin of Volgograd State Medical University. 2018;(3):67–68. (In Russ).
  13. Dremova NB. Medical and pharmaceutical commodity science: textbook (course). Kursk: Kursk State Medical University; 2005. (In Russ).
  14. Dsm.ru/docs/analytics/2019_Report_rus_2019.pdf [internet]. Russian pharmaceutical market. [cited 2020 Dec 07]. Available from: https://dsm.ru/docs/analytics/2019_Report_rus_2019.pdf
  15. Romanov BK, Toropova II, Kolesnikova EY. Missuse of drugs. Safety and risk of pharmacotherapy. 2014;(2):28–30. (In Russ).

Supplementary files

Supplementary Files
Action
1. Fig. 1. Holders of registration certificates for antidysrhythmic drugs (%).

Download (99KB)
2. Fig. 2. Positions (1–20) of the drug “Concor” in the monthly schedule of pharmacy sales in 2018 and 2019.

Download (88KB)

Statistics

Views

Abstract: 124

PDF (Russian): 2

Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.

Copyright (c) 2021 Eco-Vector



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies